Cephamycin (2nd-gen-like, anaerobic cover)
Cefoxitin
Brand names: Mefoxin
Adult dose
Dose: 1–2g IV/IM q6–8h (max 12g/day)
Route: IV / IM
Frequency: q6–8h
Clinical pearls
- BSAC / UKHSA: surgical prophylaxis for colorectal / pelvic surgery (B. fragilis cover)
- Less commonly used in UK vs co-amoxiclav / metronidazole-based regimens
Contraindications
- Severe beta-lactam hypersensitivity
Side effects
- GI upset
- Hypersensitivity
- Phlebitis
- C. difficile
- Eosinophilia
Interactions
- Probenecid
Monitoring
- Resolution
- C. diff
Reference: BNF; BSAC; UKHSA; https://bnf.nice.org.uk/drugs/cefoxitin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023